ES-NK cell therapy for tough lupus nephritis
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new type of immune cell therapy (called ES-NK cells) for people with a severe form of lupus nephritis that hasn't improved with standard treatments. The goal is to see if these cells can reduce kidney inflammation and improve lupus symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 5 and 35 years old.
- You must have lupus nephritis (kidney inflammation from lupus) that is active, with a kidney biopsy in the last 2 years showing a specific type (Class III or IV).
- You must have tried standard treatments that didn't control the disease, or you are newly diagnosed.
- You must have positive ANA antibodies and either anti-dsDNA or anti-Sm antibodies in your blood.
- You must not be on dialysis or need dialysis during the trial.
- You must be willing to use effective birth control for at least 1 year after the treatment if you can have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new therapy called NKX019, which uses specially engineered natural killer cells to target a protein on lupus cells. It is for people with moderate to severe lupus that has not responded to standard treatments, especially those with active kidney inflammation.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
This trial tests a new kind of treatment called CRC01, which uses your own immune cells modified to attack and calm the overactive immune system that causes lupus. It's for people with severe lupus that affects the kidneys and hasn't improved with standard therapies, and it aims to reduce disease activity and prevent further damage.
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
This trial tests a new cell therapy (RY_SW01) for people with active lupus nephritis (kidney inflammation caused by lupus) who haven't responded well to standard treatments. It aims to see if the therapy can help control the disease.
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
Hear when a new Systemic Lupus Erythenlatosus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.